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Digital Lung Auscultation: Will Early Diagnosis of
Fibrotic Interstitial Lung Disease Become a Reality?
To the Editor:
Interstitial lung diseases (ILDs) are a heterogeneous group of lung
disorders that are often associated with substantial morbidity and
early mortality. Pulmonary fibrosis is characteristic of most ILDs,
and preliminary data suggest that early diagnosis and prompt
intervention can improve clinical outcomes (1).
Idiopathic pulmonary fibrosis (IPF), one of the most common
and best-studied forms of ILD, has a median estimated survival of
2–5 years from diagnosis (2). Delayed referral to a tertiary care
center may be associated with higher mortality, irrespective of
disease severity (3).
Early detection is essential to establish an accurate diagnosis
and ensure timely intervention with appropriate treatment, as there
are antifibrotics that have been approved for IPF (pirfenidone and
nintedanib) and are effective in slowing disease progression (4) but
do not reverse fibrosis. In addition, the decline in lung function for
patients with IPF and preserved lung volume seems to be similar to
that observed in those with more impaired lung volume
(z200 ml/yr), and both groups appear to benefit equally from
antifibrotic treatment (5).
Furthermore, patients with advanced IPF are more likely
to discontinue treatment (6), adding to the rationale for earlier
intervention. Here we discuss the potential role of digital lung
auscultation as an aid to support the early identification of patients
with suspected fibrotic ILD.
Early Diagnosis of IPF Is Challenging
Most patients experience significant challenges in their pursuit of a
correct diagnosis of IPF (7). The nonspecific symptoms of IPF,
including cough and insidiously progressive dyspnea, usually lead
to repeated physician visits and multiple diagnostic tests, with
misdiagnoses being commonplace (7).
Specific diagnostic procedures, such as chest high-resolution
computed tomography (HRCT) to detect the patterns of usual
interstitial pneumonia, lung biopsy, and multidisciplinary
discussions, are recommended for an accurate diagnosis of IPF.
Consideration of demographic and clinical data also improves
diagnostic confidence (8).
Identification of interstitial lung abnormalities (ILAs), defined
as the presence of specific patterns on chest computed tomography,
may offer a strategy for early detection of IPF (9). The feasibility of
this approach is dependent on an improved understanding of ILA
subgroups and the nature of disease progression (9).
Rationale for the Use of Digital Lung Auscultation
Earlier access to a tertiary care center might be facilitated by
improved methods of lung sound detection, including the
recognition of so-called “Velcro-like” crackles, a hallmark feature
that is present early in the disease course of IPF and in many
fibrotic ILDs (10).
A subjective assessment of Velcro-like crackles bilaterally on
chest auscultation predicts the presence of fibrotic ILD and usual
interstitial pneumonia patterns on HRCT (10, 11), and is associated
with varying degrees of different ILAs (10). Hence, Velcro-like
crackles may provide a rationale for investigating lung sounds to
accurately identify patients with ILD, and could even be used as a
screening aid. It has been suggested that the presence or absence of
fine Velcro-like crackles at lung auscultation should be considered
in the management of subjects with (sub)clinical ILD (12).
Methods for quantitative analysis of lung sounds have been
shown to distinguish the Velcro-like crackles found in IPF from the
lung sounds present in other pulmonary conditions that cause
similar symptoms (13); research in this area is ongoing.
There is a clear need for further, clinically oriented, prospective
studies to clarify the limitations and potential of the existing data.
Previous studies have been affected by extensive variability in the
methods used and features investigated; the complexity of the
recording systems used (e.g., multichannel analyzers and air-
coupled sensors); and a lack of robust diagnostic research designs for
small, preselected study populations, usually with inappropriate
reference to diagnostic standards.
Steps Needed to Bring Digital Lung Auscultation into
Clinical Practice
Research projects are under way to build more evidence in this
field. In an ongoing, multicenter clinical trial (clinicaltrials.gov
identifier: NCT03503188), digital lung sounds and basic patient
characteristics are being prospectively collected from patients with
IPF and symptom-matched control subjects. A well-established
teaching device for lung sounds (14) will be used as a reference.
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The development and validation of supervised classification
algorithms, using HRCT imaging as a reference, will assist the
development of a digital auscultation aid to support the
detection of specific acoustic patterns in IPF and facilitate early
diagnosis (Figure 1). From a practical standpoint, we propose
that such a tool should ultimately consist of a commercially
available digital stethoscope (or alternatively a digital
transductor connected to a standard stethoscope) and a software
application to provide easy readouts of the probability of
fibrotic lung disease. If validated, a digital device incorporating
acoustic and readily available clinical data might provide
an unprecedented opportunity to perform cost-effective,
noninvasive screening of fibrotic ILD in at-risk populations.
Indeed, we anticipate that the next greatest challenge will be to
prove the effectiveness of such a tool in clinical practice, ideally
requiring its implementation in primary care settings and
a comparison with standard of care. The use of open-source
platforms should also be strongly encouraged throughout the
whole process to maximize refinement of the tool’s diagnostic
performance.
Digital lung sounds may have potential not only as a diagnostic
aid but also as a quantitative methodology for monitoring disease
progression in IPF (15). A correlation between lung sound changes
and disease behavior has been shown in a proof-of-concept study
(16), and further research is warranted.
Conclusions
By the time IPF is diagnosed, the patient’s prognosis is often poor,
and an opportunity for early treatment has been missed. As Velcro-
like crackles on lung auscultation are present early in the disease
course, digital assessment of patients’ lung sounds, cross-referenced
with a validated database of sounds from healthy lungs, different
diseases, and other ILDs, may enable earlier and more accurate
diagnosis and intervention. Artificial intelligence will hopefully aid
in the development of accurate diagnostic algorithms based on
digital auscultation data. Therefore, the development of a digital
auscultation diagnostic aid has the potential to improve the
care of patients with IPF and, conceivably, pulmonary fibrosis in
general. n
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Figure 1. Potential role of digital lung auscultation in the management of patients with idiopathic pulmonary fibrosis. *Surgical lung biopsy is not suitable
for all patients. HRCT=high-resolution computed tomography; IPF= idiopathic pulmonary fibrosis; MDD=multidisciplinary discussion; UIP= usual
interstitial pneumonia. Reprinted from Reference 8.
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Fever in Sepsis: Still a Hot Topic
To the Editor:
With great interest, we read the paper by Bhavani and colleagues
(1), who report a novel method to distinguish between sepsis
phenotypes based on body temperature. Using trajectory
modeling, the authors identify four phenotypes, each displaying
distinct demographic characteristics, physiological parameters,
and prognosis. The data presented reveal that the so-called
hyperthermic, fast resolving patients, who presented with a
high temperature that decreased rapidly afterward, had the
lowest in-hospital mortality. In addition, a more swift
increase in temperature was also positively related to
survival. The authors plausibly argue that hyperthermic, fast
resolvers may be able to mount a strong, but nevertheless well-
balanced, inflammatory response, resulting in a better clinical
outcome.
What is currently missing is more solid evidence for whether or
not there is an immunological basis for the proposed temperature-
based phenotypes. Insight into the release of so-called endogenous
pyrogens (2), mainly represented by cytokines such as TNFa
(tumor necrosis factor a) and IL-6, could provide the missing link
between the underlying immune status and the body temperature
trajectories observed.
In the experimental human endotoxemia model, Escherichia
coli endotoxin is administrated intravenously to healthy
volunteers, inducing a standardized short-lasting systemic
inflammatory response, which captures relevant hallmarks of the
immune response observed in patients with sepsis (3). Serial
measurements of cytokines and body temperature during
endotoxemia allow for determination of their relationship.
Using data from 20 male subjects allocated to the control
group (no intervention other than bolus administration of
1 ng/kg endotoxin followed by continuous infusion of 1 ng/kg/h
endotoxin over the course of 3 h) of a recent interventional study
performed by our group (4), we analyzed the relationship between
peak plasma cytokine concentrations and body temperature
changes over time. We divided the subjects according to the
median cytokine levels, resulting in 10 low and 10 high cytokine
producers, and calculated the slope of the endotoxin-induced
temperature increase (Tempslope =D temperature increase/time to
peak temperature).
On average, plasma concentrations of TNFa, IL-6, and IL-10
reached their maximum at 2.5, 3, and 3.5 hours after endotoxin
administration, respectively, whereas peak temperatures were
observed 4 hours after endotoxin. Tempslope strongly correlated
with peak temperature (Spearman r = 0.92; P, 0.0001). In
subjects who produced high levels of the proinflammatory
cytokines IL-6 and TNFa, Tempslope was significantly higher
than in low proinflammatory cytokine producers, whereas
Tempslope did not differ between low and high producers of
antiinflammatory IL-10 (Figure 1). Spearman correlation
coefficients for the relationship between cytokines and
Tempslope were r = 0.75 for IL-6 (P, 0.0001) and r = 0.52
for TNFa (P = 0.02). Furthermore, peak temperatures were
reached earlier by high IL-6 and TNFa producers (high
responders: 3.66 0.1 vs. low responders: 4.56 0.2 h [P = 0.002]
and high responders: 3.76 0.2 vs. low responders: 4.46 0.2 h
[P = 0.02], respectively). After the peak, temperatures
gradually normalized, but the slope of the temperature
decrease did not correlate with levels of any of the measured
cytokines.
Taken together, these findings indicate that indeed higher levels
of proinflammatory, but not antiinflammatory, cytokines precede
a more potent and swift temperature increase. These data provide
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